Psoriasis Disease Pipeline Drugs Assessment:  By Trial Phase (Preclinical Trials, Phase 1, Phase 2, Phase 3, Phase 4) By Drugs (Icotinib Hydrochloride, Bimekizumab, Calcipotriene ,Ustekinumab, Risankizumab, Methotrexate, Others) Condition (Plaque psoriasis, Scalp psoriasis, Guttate psoriasis, Nail psoriasis, Inverse psoriasis, Pustular psoriasis, Erythrodermic psoriasis, Psoriatic arthritis), Route of Administration (Oral, Parenteral) and Geography [urltag] [urltag url='request-methodology'] Request Sample Read More

Purchase Option

$ 4400
$ 4000
$ 6000

Psoriasis Disease Pipeline Drugs



Psoriasis is a genetic inflammatory diseases which affects skin. Psoriasis is charecterised by skin cells that multiply up to 10 times faster than normal. When these cells reach surface and die, raised, red plaques covered with white scales for. Psoriasis begins as a small scaling papule. When multiple papules coalesce, they form scaling plaques. These plaques tend to occur in the scalp, elbows, and knees.

Symptoms includes red patches on skin, small scaling spots, dry and cracked skin, burning, itching and soreness of skin, bleeding etc. Psoriasis is diagnosed by physical examination and skin biopsy. Psoriasis is treated by topical corticosteroids, Vitamin D analogues,Topical retinoids, Calcineurin inhibitors etc. and it can be treated by phototherapy



By Trial Phase, Psoriasis pipeline drugs are segmented as:

  • Preclinical Trials
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Company, Psoriasis pipeline drugs are segmented as:

  • Galderma
  • Arcutis, Inc.
  • Almirall, S.A.
  • proDERM GmbH
  • Novartis Pharmaceuticals
  • GlaxoSmithKline
  • Janseen
  • AbbVie
  • Boehringer Ingelheim
  • Others

By Drugs, Psoriasis pipeline drugs are segmented as:

  • Icotinib Hydrochloride
  • Bimekizumab
  • Calcipotriene
  • Ustekinumab
  • Risankizumab
  • Methotrexate
  • Others

By Type of Condition, Psoriasis pipeline drugs are segmented as:

  • Plaque psoriasis
  • Scalp psoriasis
  • Guttate psoriasis
  • Nail psoriasis
  • Inverse psoriasis
  • Pustular psoriasis
  • Erythrodermic psoriasis
  • Psoriatic arthritis

By Route of Administration, Psoriasis pipeline drugs are segmented as:

  • Oral
  • Parenteral


Space Analysis:

  • In November 2016,Janssen-Cilag submitted Marketing Authorisation Application to the European Medicines Agency (EMA) seeking approval of CNTO 1959 (guselkumab) for the treatment of adults living with moderate to severe plaque psoriasis
  • In March 2016, Dr. Reddy's Laboratories and XenoPort, Inc. entered into a license agreement pursuant to which Dr. Reddy’s Laboratories will be granted exclusive U.S. rights for the development and commercialization of XenoPort’s clinical-stage oral new chemical entity, XP23829. Dr. Reddy’s Laboratories plans to develop XP23829 as a potential treatment for moderate-to-severe chronic plaque psoriasis

Report Description:

Psoriasis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Psoriasis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Psoriasis disease pipeline drugs development. This report studies the dynamics of the Psoriasis Disease Pipeline Drugs i.e. drivers, challenges and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Psoriasis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.


Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis on the each drug candidates in the clinical trial phases



PBI Location Map

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

[urltag url='request-table-of-content']

  • Galderma
  • Arcutis, Inc.
  • Almirall, S.A.
  • proDERM GmbH
  • Novartis Pharmaceuticals
  • GlaxoSmithKline
  • AbbVie
  • BoehringerIngelheim
  • Others

Adjacent Markets